Free Trial
NASDAQ:LIAN

LianBio (LIAN) Stock Price, News & Analysis

LianBio logo
$0.29 0.00 (0.00%)
(As of 11/20/2024 ET)

About LianBio Stock (NASDAQ:LIAN)

Key Stats

Today's Range
$0.29
$0.30
50-Day Range
$0.28
$0.36
52-Week Range
$0.27
$4.99
Volume
25,043 shs
Average Volume
1.04 million shs
Market Capitalization
$31.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50
Consensus Rating
Reduce

Company Overview

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

LianBio Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
22nd Percentile Overall Score

LIAN MarketRank™: 

LianBio scored higher than 22% of companies evaluated by MarketBeat, and ranked 863rd out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    LianBio has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    LianBio has received no research coverage in the past 90 days.

  • Read more about LianBio's stock forecast and price target.
  • Earnings Growth

    Earnings for LianBio are expected to decrease in the coming year, from $2.40 to ($0.86) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of LianBio is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of LianBio is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    LianBio has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for LIAN.
  • Dividend Yield

    LianBio does not currently pay a dividend.

  • Dividend Growth

    LianBio does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for LIAN.
  • MarketBeat Follows

    1 people have added LianBio to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, LianBio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.59% of the stock of LianBio is held by insiders.

  • Percentage Held by Institutions

    74.85% of the stock of LianBio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about LianBio's insider trading history.
Receive LIAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LianBio and its competitors with MarketBeat's FREE daily newsletter.

LIAN Stock News Headlines

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…
Why Is LianBio (LIAN) Stock Moving Today?
LianBio Announces Voluntarily Delisting from Nasdaq
See More Headlines

LIAN Stock Analysis - Frequently Asked Questions

LianBio's stock was trading at $4.47 on January 1st, 2024. Since then, LIAN shares have decreased by 93.6% and is now trading at $0.2879.
View the best growth stocks for 2024 here
.

LianBio (NASDAQ:LIAN) released its earnings results on Monday, March, 27th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.10.

LianBio (LIAN) raised $325 million in an initial public offering (IPO) on the week of November 1st 2021. The company issued 20,300,000 shares at $16.00 per share. Goldman Sachs, Jefferies and BofA Securities acted as the underwriters for the IPO.

Shares of LIAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that LianBio investors own include Arista Networks (ANET), NVIDIA (NVDA), ServiceNow (NOW), Broadcom (AVGO), Novo Nordisk A/S (NVO), PACCAR (PCAR) and Super Micro Computer (SMCI).

Company Calendar

Last Earnings
3/27/2023
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LIAN
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.50
High Stock Price Target
$4.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+1,115.5%
Consensus Rating
Reduce
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

Net Income
$-110,290,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.71 per share

Miscellaneous

Free Float
99,861,000
Market Cap
$31.12 million
Optionable
Not Optionable
Beta
0.23
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:LIAN) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners